Epiomic Epidemiology Series: Uveitis Forecast in 18 Major Markets 2018–2028

January 2018 | 84 pages | ID: E090582AFA5EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Uveitis in 18 Major Markets

Uveitis is a general term denoting a group of inflammatory conditions of the eye. It affects mainly the uvea, a structure comprising the iris, ciliary body and choroid, but it can also affect nearby structures within the eye: the retina, vitreous humour and optic nerve. The condition constitutes a major cause of vision loss and blindness worldwide, but is thought to receive insufficient attention of healthcare professionals not specialised in ophthalmology. This report covers uveitis of immune and infectious origin, while excluding traumatic and post-operative uveitis, as well as Fuchs’ heterochromic iridocyclitis.

This report provides the current prevalent population for uveitis across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, uveitis categories based on location and aetiology, several features of uveitis patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of uveitis include:

• Autoimmune diseases (systemic)
• Ocular hypertension
• Macular oedema
• Epiretinal membrane
• Diabetes mellitus
• Tuberculosis and other infections

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global uveitis market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of uveitis and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of uveitis patients.
• Identification of uveitis patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of uveitis patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

STANDARDISATION OF UVEITIS NOMENCLATURE (SUN) WORKING GROUP GUIDELINES

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR UVEITIS

FEATURES OF UVEITIS PATIENTS

AETIOLOGY OF UVEITIS

INFECTIOUS CAUSES OF UVEITIS

AUTOIMMUNE CAUSES OF UVEITIS

VISION LOSS IN UVEITIS

COMORBID OPHTHALMIC CONDITIONS IN UVEITIS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Signs and symptoms of uveitis by the affected section of the eye
Table 2. The SUN working group descriptors of uveitis
Table 3. Prevalence of uveitis, total (000s)
Table 4. Prevalence of uveitis, males (000s)
Table 5. Prevalence of uveitis, females (000s)
Table 6. Patients with uveitis by anatomical site, total (000s)
Table 7. Patients with anterior uveitis by aetiology, total (000s)
Table 8. Patients with anterior uveitis by duration of attack, total (000s)
Table 9. Patients with intermediate uveitis by aetiology, total (000s)
Table 10. Patients with posterior uveitis by aetiology, total (000s)
Table 11. Patients with panuveitis by aetiology, total (000s)
Table 12. Patients with infectious uveitis by causal agent, total (000s)
Table 13. Patients with autoimmune uveitis by causal condition, total (000s)
Table 14. Uveitis patients with vision loss (acuity ≤6/18), total (000s)
Table 15. Uveitis patients with vision loss (acuity ≤6/18) by laterality, total (000s)
Table 16. Uveitis patients with vision loss (acuity ≤6/18) by cause, total (000s)
Table 17. Uveitis patients with hypopyon, total (000s)
Table 18. Uveitis patients with ocular hypertension, total (000s)
Table 19. Uveitis patients with macular oedema, total (000s)
Table 20. Uveitis patients with epiretinal membranes, total (000s)
Table 21. Abbreviations and acronyms used in the report
Table 22. USA prevalence of uveitis by 5-yr age cohort, males (000s)
Table 23. USA prevalence of uveitis by 5-yr age cohort, females (000s)
Table 24. Canada prevalence of uveitis by 5-yr age cohort, males (000s)
Table 25. Canada prevalence of uveitis by 5-yr age cohort, females (000s)
Table 26. France prevalence of uveitis by 5-yr age cohort, males (000s)
Table 27. France prevalence of uveitis by 5-yr age cohort, females (000s)
Table 28. Germany prevalence of uveitis by 5-yr age cohort, males (000s)
Table 29. Germany prevalence of uveitis by 5-yr age cohort, females (000s)
Table 30. Italy prevalence of uveitis by 5-yr age cohort, males (000s)
Table 31. Italy prevalence of uveitis by 5-yr age cohort, females (000s)
Table 32. Spain prevalence of uveitis by 5-yr age cohort, males (000s)
Table 33. Spain prevalence of uveitis by 5-yr age cohort, females (000s)
Table 34. UK prevalence of uveitis by 5-yr age cohort, males (000s)
Table 35. UK prevalence of uveitis by 5-yr age cohort, females (000s)
Table 36. Poland prevalence of uveitis by 5-yr age cohort, males (000s)
Table 37. Poland prevalence of uveitis by 5-yr age cohort, females (000s)
Table 38. Netherlands prevalence of uveitis by 5-yr age cohort, males (000s)
Table 39. Netherlands prevalence of uveitis by 5-yr age cohort, females (000s)
Table 40. Turkey prevalence of uveitis by 5-yr age cohort, males (000s)
Table 41. Turkey prevalence of uveitis by 5-yr age cohort, females (000s)
Table 42. Japan prevalence of uveitis by 5-yr age cohort, males (000s)
Table 43. Japan prevalence of uveitis by 5-yr age cohort, females (000s)
Table 44. China prevalence of uveitis by 5-yr age cohort, males (000s)
Table 45. China prevalence of uveitis by 5-yr age cohort, females (000s)
Table 46. South Korea prevalence of uveitis by 5-yr age cohort, males (000s)
Table 47. South Korea prevalence of uveitis by 5-yr age cohort, females (000s)
Table 48. India prevalence of uveitis by 5-yr age cohort, males (000s)
Table 49. India prevalence of uveitis by 5-yr age cohort, females (000s)
Table 50. Australia prevalence of uveitis by 5-yr age cohort, males (000s)
Table 51. Australia prevalence of uveitis by 5-yr age cohort, females (000s)
Table 52. Brazil prevalence of uveitis by 5-yr age cohort, males (000s)
Table 53. Brazil prevalence of uveitis by 5-yr age cohort, females (000s)
Table 54. Mexico prevalence of uveitis by 5-yr age cohort, males (000s)
Table 55. Mexico prevalence of uveitis by 5-yr age cohort, females (000s)
Table 56. Argentina prevalence of uveitis by 5-yr age cohort, males (000s)
Table 57. Argentina prevalence of uveitis by 5-yr age cohort, females (000s)
Figure 1. Colour representation of the eye sections affected by each anatomical category of uveitis: blue—anterior uveitis, green—intermediate uveitis, purple—posterior uveitis; panuveitis encompasses all three sections